Abstract. New imaging methods are urgently needed to identify highrisk atherosclerotic lesions prior to the onset of myocardial infarction, stroke, and ischemic limbs. Molecular imaging offers a new approach to visualize key biological features that characterize high-risk plaques associated with cardiovascular events. While substantial progress has been realized in clinical molecular imaging of plaques in larger arterial vessels ͑carotid, aorta, iliac͒, there remains a compelling, unmet need to develop molecular imaging strategies targeted to high-risk plaques in human coronary arteries. We present recent developments in intravascular near-IR fluorescence catheter-based strategies for in vivo detection of plaque inflammation in coronary-sized arteries. In particular, the biological, light transmission, imaging agent, and engineering principles that underlie a new intravascular near-IR fluorescence sensing method are discussed. Intravascular near-IR fluorescence catheters appear highly translatable to the cardiac catheterization laboratory, and thus may offer a new in vivo method to detect high-risk coronary plaques and to assess novel atherosclerosis biologics.
Molecular Imaging of Atherosclerosis: Motivations
Progression of asymptomatic atherosclerotic lesions is the predominant cause of myocardial infarction, stroke, and ischemic limbs. As such life-threatening events continue to occur despite advances in medical therapies, identification of high-risk lesions will be critical in preventing the occurrence of devastating cardiovascular events. Current atherosclerosis imaging strategies focus largely on the anatomic and physiologic characteristics of vessel narrowing as a consequence of vessel stenosis. While useful, these approaches provide little insight into the biology of atherosclerosis, a critical aspect of plaque progression and complications. 1 Identifying the molecular or cellular determinants of high-risk ͑or "vulnerable"͒ plaques therefore appears a logical approach to understanding and treating atherosclerosis. 2 Toward this end, in vivo molecular imaging is a promising strategy to identify key biological processes that govern atherosclerosis, including inflammation, apoptosis, oxidative stress, and angiogenesis. 3, 4 
Imaging of Atheroma Inflammation
Atherosclerosis is an inflammatory disease driven by the unregulation of leukocyte adhesion molecules and subsequent recruitment of macrophages and T cells within the vessel wall. 1 Once resident in the intima, macrophages imbibe lipid, promoting lipid-laden foam cell formation, smooth muscle proliferation, and localized and systemic inflammation typified by the production of destabilizing proteases, cytokines, and oxidants. Nascent atheromata consequently undergo expansive ͑positive͒ remodeling, and years later undergo constrictive ͑negative͒ remodeling that results in stenosis formation. During this transformative period, plaques may demonstrate high-risk features including inflammation, a large necrotic core, and a thin fibrous cap. 2 Such plaques, termed high-risk or vulnerable, may become acutely disrupted, leading to thrombus formation and acute myocardial infarction.
The inflammatory cascade has yielded a number of highsensitivity molecular imaging targets. 3, 4 Macrophages are the critical effectors cell in atherosclerosis and have been clinically imaged by positron emission tomography ͑PET͒, magnetic resonance imaging ͑MRI͒, and nuclear approaches. Imaging of augmented protease activities ͑cysteine proteases, matrix metalloproteinases͒ that destabilize the fibrous cap overlying plaques is a promising, translatable, near-IR fluorescence ͑NIRF͒ imaging method to detect plaque inflammation. Leukocyte adhesion molecules ͓e.g., vascular cell adhesion molecule ͑VCAM͒-I͔ are another attractive imaging target due to their ability to report on early plaque inflammation, and have been imaged by MRI, NIRF, and ultrasound molecular imaging approaches. In addition, strategies to identify plaque apoptosis, accumulation of oxidized lipids, and angiogenesis are exciting options to identify high-risk plaques. For a detailed discussion of molecular imaging agent reporters for atherosclerosis, see several recent reviews. 
NIRF as a Molecular Imaging Platform
NIRF imaging has emerged as powerful in vivo approach for molecular imaging of atherosclerosis, due to ͑1͒ its high intrinsic ͑picomolar͒ sensitivity, ͑2͒ a broad array of attachment chemistries for targeted and activatable imaging agents ͑dis-cussed later in this paper͒, ͑3͒ efficient transmission of light in the near-IR ͑NIR͒ window, ͑4͒ a wide array of detection systems spanning ultrahigh resolution ͑confocal microscopy͒ to mesoscopic resolution ͑e.g., catheter-based reflectance imaging͒ to macroscopic resolution ͑e.g., fluorescence molecular tomography͒, and ͑5͒ substantial clinical translational capabilities from both a hardware standpoint ͑e.g., NIRF catheters based on clinical catheters for optical coherence tomography͒ and imaging agent standpoint ͓i.e., indocyanine green, a NIR fluorochrome that is Food and Drug Administration ͑FDA͒ approved for retinal angiography͔.
Photonic Transmission in the NIR Window
Compared to the visible light range, the NIR spectral region, and more specifically the 650 to 950-nm window, offers attractive characteristics for optical imaging due to lower light absorption by hemoglobin in this wavelength band. This enables practical photon detection even after propagation through several centimeters in tissue, for example, through more than 10 cm in the human breast [5] [6] [7] and more than 3 to 4 cm in muscle tissue or in functional brain measurements. 8 By comparison, depths of only a few millimeters of tissue can be visualized with similar SNR statistics in the blue, green, or red light regions, although the exact penetration depth remains strongly dependent on the wavelength selection.
The NIR region is similarly crucial when considering intravascular applications. While the geometrical dimensions in catheter-based vessel imaging are significantly reduced compared to breast or brain imaging applications, the blood concentration within vessels is significantly higher than in breast, brain, or muscle tissue, leading to a corresponding increase in the absorption coefficient. It is therefore important to utilize NIR wavelengths to achieve high sensitivity through whole blood. In addition, tissue exhibits reduced autofluorescence in the NIR compared to the visible light range. 9 This advantage augments the contrast available to imaging and reduces the need for multispectral methods that may otherwise be necessary to decompose the effects of autofluorescence from the signal detected from a reporter fluorochrome.
Protease-Activatable NIRF Imaging Agents
The chemical design of a new class of activatable imaging agents based on protease-mediated cleavage of quenched substrates has dramatically improved the sensitivity of in vivo NIRF imaging. Protease-activatable probes are comprised of 15 to 20 NIR fluorochromes that are conjugated to a high molecular weight ͑ϳ500 kD͒ methyl poly-͑ethylene glycol͒ ͑MPEG͒ poly-L-lysine backbone. A radio labeled version of this backbone safely completed clinical trials. 10 As the fluorochromes exist in close proximity, self-quenching of the molecule occurs, leading to an optically "silent" imaging agent. As opposed to conventional fluorochromes ͑or radioisotopes, magnetic reporters, or microbubbles͒, these quenched fluorescence substrates generate minimal background signal after injection into the body. In a suitable protease-rich environment, cleavage of the quenched substrate occurs, liberating fluorescence. As opposed to imaging agents that report on protease presence with active site-binders, 11, 12 the background signal of the uncleaved NIRF activatable agent is minimal due to its engineered autoquenched design, and high target-tobackground ratios are achievable in vivo. 13 In particular, in vivo imaging of inflammatory plaques using activatable NIRF probes targeted to cysteine and matrix metalloproteinases ͑MMPs͒ have yielded promising results by both intravital fluorescence microscopy ͑IVFM͒ and fluorescence molecular tomography ͑FMT͒ detection.
14-16 A firstgeneration activatable NIRF agent targeted to multiple cathepsins 13, 14 ͑cathepsin B, L, S͒ is now under development for clinical trials for both vascular and cancer applications. 3 By interspersing an oligopeptide construct into the MPEG backbone, second-generation NIRF activatable agents can be constructed with specificities for gelatinase activity 15 ͑MMP-2, MMP-9͒ and cathepsin K. 16 In addition, other protease activities have also been imaged using secondgeneration NIRF activatable reporters such as thrombin, 17 cathepsin D, 18 urokinase-type plasminogen activator, 19 and cathepsin S. 
Intravascular NIRF Catheter Sensing of Inflammation in Coronary-Sized Vessels
A recently tested NIRF catheter offers a new invasive molecular imaging approach to visualize atheroma inflammation in vivo through blood in coronary-sized vessels.
21,22

NIRF Catheter Design
The first-generation coronary artery compatible guidewire is based 22 on a clinically translatable optical coherence tomography ͑OCT͒ platform ͑Fig. 1͒. The catheter utilizes as an excitation source a laser diode at a 750 nm ͑B&W TEK, Newark, New Jersey͒ and it collects fluorescence signal at 780 nm. As the excitation and the emission channels are spectrally close to each other, the laser light is first filtered with a narrow-bandpass interference filter centered at 752 nm and with a 5-nm full width at half maximum ͑FWHM͒ to remove any residual laser emission present in the fluorescence detec-tion channel. Excitation light is then coupled into a system delivery fiber after passing through a 3-dB beamsplitter and coupled into the dedicated catheter based on an optical coherence tomography wire ͑LightLab Imaging Inc., Westford, Massachusetts͒. The catheter is comprised of a 0.36-mm/ 0.014-in. radiopaque floppy tip that allows for x-ray detection, and a 0.48-mm/ 0.019-in. outer diameter housing containing a 62.5/ 125-m multimode fiber for maximal light collection.
A prism at the end of the catheter directs the light at 90 deg with respect to the catheter axis and focuses the light on a focal spot size of around 40 m diameter at a working distance of 2 mm. The fluorescent light emitted by the contrast agent present within the plaque is then collected back into the catheter, guided to the beamsplitter, and coupled into a separate multimode fiber. The fluorescence signal is next filtered with a dielectrically coated dichroic filter with a cut-on wavelength of 780 nm to remove any further residual excitation laser component. A sensitive photomultiplier tube ͑H5783-20, Hamamatsu, Shizuoka, Japan͒ then detects the residual filtered light.
Phantom Simulations of Blood and Tissue Attenuation of NIR Light
The effects of blood and tissue on NIRF signal attenuation were tested using a home-built atherosclerotic vessel wall phantom with fresh rabbit blood, simulated tissue, and a NIRF plaque ͑Fig. 1͒. The plaque consisted of a cuvette filled with a solution of 1% Intralipid ͑Liposyn, Hospira Inc., Lake Forest, Illinois͒ and 50 ppm India ink ͑Faber-Castell, Cleveland, Ohio͒ to match the optical parameters of tissue Chemical Co. Inc., Milwaukee, Wisconsin͒ and India ink. The imaging catheter was next immersed in the vessel phantom ͑a large container filled with rabbit blood͒ at variable distances from the NIR fluorescent plaque. As expected, NIR fluorescence light attenuated as function of increasing distance. However, notably, the effects of blood compared to saline were modest in the NIR with decay distance ͑1 / e͒ of 500 m compared with a decay distance of 700 m in saline ͑Fig. 1͒, affirming the favorable photonic transmission properties of the NIR window. The tissue ͑T͒ thickness, reflecting a simulated fibrous cap overlying the fluorescent plaque, also produced only modest effects on the NIRF signal at a 500-m thickness. These experiments demonstrated the feasibility of NIR light detection through intravascular volumes of blood relevant for atherosclerotic plaques.
Real-Time Intravascular Sensing of NIRF Signals Emanating from Inflamed Plaques
The first in vivo application of the NIRF catheter was demonstrated using atherosclerotic rabbits harboring inflamed atheromata. 22 Angiographically visible lesions were produced by balloon injury of the iliac arteries followed by hypercholesterolemia for 8 weeks ͑Fig. 2͒. Twenty-four hours prior to in vivo experiments, rabbits received an injection of a firstgeneration cysteine protease-activatable NIRF agent ͑Prosense750, VisEn Medical͒. The NIRF catheter was then advanced percutaneously into the iliac arteries under x-ray fluoroscopic guidance. Manual, repeated digitized pullbacks and voltage recordings were obtained through blood, without balloon occlusion or saline flushing ͑Fig. 2͒. In vivo TBRs were calculated in both normal and diseased segments. NIRF signal profiles readily distinguished atheroma from normal segments, as well as from atheroma of saline-injected control rabbits. High in vivo plaque TBRs were detected with values of 6.8Ϯ 1.9, compared to saline controls of 1.3Ϯ 0.3 ͑p Ͻ 0.05͒. To confirm that augmented voltage was plaque specific, the catheter was readvanced to lesions visible on the angiogram. The static NIRF signal was recorded adjacent to plaques and to normal-appearing vessel wall areas on angiography.
To further assess the effect of blood absorption on the detected NIRF signal, vessel occlusion and saline flushing ͑3 ml over 4 s͒ were performed through a balloon wedge catheter. In the protease agent group only, differences in flush profiles were evident between plaque areas and normal segments. In plaque areas, saline flushing augmented the detected NIRF signal with a peak signal increase of up to 74Ϯ 18%. In the protease agent group, macroscopic fluorescence reflectance imaging ͑FRI͒ revealed NIRF signal in plaques but not in the uninjured, normal-appearing vessel segment. The in vivo and ex vivo peak plaque TBRs correlated well ͑r = 0.82, p Ͻ 0.01͒, demonstrating reasonable in vivo quantification methodology. In vitro histopathology confirmed colocalization of NIRF signal with cathepsin B and macrophages within atheroma ͑Fig. 3͒, and demonstrated reduced plaque autofluorescence in the NIR range compared to the visible range, as expected. 22 This study thus provided the first demonstration of in vivo molecular imaging of plaque inflammation in coronary-sized vessels. Due to the ability to obtain high TBRs in vivo through blood in real time, this approach appears promising for rapid coronary artery screening in vivo. Additional studies will clarify the attenuation effects of blood in larger vessels ͑e.g., 3.5 mm diameter͒ than tested in this study ͑2.25 to 2.5 mm diameter͒.
Intravascular NIRF Catheter Design: Future Directions
While original intravascular fluorescence imaging designs 21, 22 have demonstrated feasibility based on 1-D signal acquisition, it is crucial to develop catheter systems with the ability to provide 3-D imaging of vessel segments as necessary for comprehensive coronary arterial imaging. Of importance are methodologies that can offer accurate visualization and impart quantification within the challenging imaging conditions of a blood vessel. A preferred mode of operation is the use of an enclosed rotating fiber, similar to those utilized in intravascular optical coherence tomography systems. 23 The combination of the rotating fiber with a pullback mechanism further enables the longitudinal visualization of vessels. Typically, the selection of a large fiber diameter offers high collection efficiency in multimode propagation. A crucial design parameter is the point spread function of the illumination and detection profile, in particular, the beam waist size of the focal spot and the Rayleigh length that define the metrics of energy deposition confinement on the vessel as a function of vessel diameter. Extended Rayleigh lengths ͑i.e., the length along which the beam stays focused͒ is particularly important for maintaining relative uniformity of illumination ͑energy deposition͒ and resolution during the imaging operation.
The design of rotating NIRF imaging catheters enables the possibility of seamless operation with other vessel imaging modalities, for example, with intravascular OCT, intravascular optical frequency domain imaging, 24 intravascular NIR spectroscopy, 25 or intravascular ultrasound. While chromatic aberrations of the focusing optics must be considered when markedly different spectral zones are utilized for OCT versus fluorescence imaging, the relatively relaxed optical conditions for the noncoherent fluorescence detection will allow for design practices common in currently available intravascular OCT systems. Another advance in intravascular NIRF imaging possible is to employ molecular optoacoustic imaging for visualizing common fluorochromes and other chromophoric reporter molecules, 26, 27 or tissue composition features such as fibrous and lipid components. The use of optoacoustics has the capacity to further resolve depth, reaching resolution and penetration capacity that are common to ultrasound systems, but imparting new contrast mechanisms for atherosclerosis differentiation.
Conclusions
The development of a coronary artery-compatible NIRF sensing catheter coupled with a high-sensitivity proteaseactivatable agent has enabled the real-time sensing of plaque inflammation through blood. Anticipated development of second-generation ͑imaging, multispectral, optoacoustic͒ and third-generation ͑multimodality͒ NIRF catheters are poised to enable integrated molecular and architectural assessment of coronary plaques in the cardiac catheterization laboratory. The availability of clinical coronary NIRF catheters with FDAapproved NIRF imaging agents will enable ͑1͒ new insights into atherosclerosis biology in living patients ͑in particular, the temporal and spatial characteristics of inflammation in coronary arteries͒, ͑2͒ understanding an individual plaque's risk of inducing myocardial infarction based on its underlying biological profile, and ͑3͒ assessment of novel biologics designed to attenuate inflammation in coronary atherosclerotic plaques. 
